Boston Business Journal -- Millennium Pharmaceuticals Inc. has sent a letter to health care professionals advising them to lower the dosage of the company’s cancer drug in certain patients. The drug, Velcade, is approved for the treatment of multiple myeloma and also is approved as a second-line treatment for patients with mantle cell lymphoma.
